Cardiovascular outcomes trials employing novel diabetes drugs (e.g., SGLT-2 inhibitors1–4, DPP-4 inhibitors5–8, and GLP-1 receptor agonists9–16) have been published between 2013 and today. This evidence concerns the gene SLC5A2 and diabetes mellitus.